Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the stomach or
gastro-esophageal junction with inoperable locally advanced or metastatic disease,
not amenable to curative therapy

- Measurable disease: At least 1 measurable metastatic lesion that has not been
irradiated; The lesion will be measured according to RECIST and be evaluated
radiologically within 28 days prior to study entry

- ECOG performance status of 0 or 1 at study entry

- Adequate bone marrow, liver and renal function

- Women of childbearing potential:Negative serum pregnancy test within 7 days and must
agree to use adequate contraception (barrier method of birth control) prior to study
entry, for the duration of study participation and 28 days after the last study drug
dosing

Exclusion Criteria:

- Previous chemotherapy for locally advanced or metastatic gastric cancer:prior
neoadjuvant or adjuvant chemotherapy completed at least 6 months prior to study entry
is allowed

- Previous anti-angiogenic therapy: Anti VEGF or VEGFR tyrosine kinase inhibitor such
as bevacizumab, sorafenib, sunitinib, AZD2171

- Previous total platinum dose >300 mg/m2: total prior platinum dose of ≤300 mg/m2
will be allowed in the adjuvant or neo-adjuvant setting

- Candidates for curative therapy

- Clinical or radiographic evidence of brain metastasis

- Cardiac disease; uncontrolled hypertension; hemorrhage/bleeding events

- Known or suspected allergy to any component of telatinib, cisplatin or capecitabine

- Known dihydropyrimidine dehydrogenase (DPD) deficiency

- Unable to take oral medications that could affect oral intake of capecitabine and
telatinib